lauric acid is a lipid of Fatty Acyls (FA) class. Lauric acid is associated with abnormalities such as Infection, Renal tubular disorder, Hypertensive disease, Obesity and Mycoses. The involved functions are known as Transcription, Genetic, Signal Transduction, Mutation, metaplastic cell transformation and Anabolism. Lauric acid often locates in Skin, Plasma membrane, Cytoplasmic matrix, Body tissue and Palmar surface. The associated genes with lauric acid are Gene Family, SLC33A1 gene, Homologous Gene, Open Reading Frames and P4HTM gene. The related lipids are Fatty Acids, Oleic Acids, Palmitates, Stearates and 9,11-linoleic acid.
To understand associated biological information of lauric acid, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
lauric acid is suspected in Renal tubular disorder, Hypertensive disease, Infection, Renal vascular disorder, Obesity, Mycoses and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with lauric acid
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Mahdi ES et al. | Effect of surfactant and surfactant blends on pseudoternary phase diagram behavior of newly synthesized palm kernel oil esters. | 2011 | Drug Des Devel Ther | pmid:21792294 |
Hickey AJ and Byron PR | Effect of a non-hygroscopic surfactant coating upon fluorescein absorption from the respiratory tract. | 1987 | Drug Des. Deliv. | pmid:3509343 |
Funke AP et al. | Development of matrix patches for transdermal delivery of a highly lipophilic antiestrogen. | 2003 | Drug Dev Ind Pharm | pmid:12906336 |
An NM et al. | Development of a novel soft hydrogel for the transdermal delivery of testosterone. | 2003 | Drug Dev Ind Pharm | pmid:12602497 |
Jung SY et al. | Formulation and evaluation of ubidecarenone transdermal delivery systems. | 2009 | Drug Dev Ind Pharm | pmid:19365779 |
Soler LI et al. | Transdermal delivery of alprazolam from a monolithic patch: formulation based on in vitro characterization. | 2012 | Drug Dev Ind Pharm | pmid:22204649 |
Hossain MA et al. | Effect of vehicle systems, pH and enhancers on the permeation of highly lipophilic aripiprazole from Carbopol 971P gel systems across human cadaver skin. | 2012 | Drug Dev Ind Pharm | pmid:22067044 |
Chisty MN et al. | In vitro evaluation of the release of albuterol sulfate from polymer gels: effect of fatty acids on drug transport across biological membranes. | 2002 | Drug Dev Ind Pharm | pmid:12476868 |
Abu-Huwaij R et al. | Potential mucoadhesive dosage form of lidocaine hydrochloride: II. In vitro and in vivo evaluation. | 2007 | Drug Dev Ind Pharm | pmid:17523008 |
Pattnaik S et al. | Influence of chemical permeation enhancers on transdermal permeation of alfuzosin: an investigation using response surface modeling. | 2011 | Drug Dev Ind Pharm | pmid:21446831 |
Cho YA and Gwak HS | Transdermal delivery of ketorolac tromethamine: effects of vehicles and penetration enhancers. | 2004 | Drug Dev Ind Pharm | pmid:15285328 |
Minn AL et al. | Characterization of microsomal cytochrome P450-dependent monooxygenases in the rat olfactory mucosa. | 2005 | Drug Metab. Dispos. | pmid:15879494 |
Pan J et al. | Lipopolysaccharide-mediated modulation of cytochromes P450 in Stat1 null mice. | 2003 | Drug Metab. Dispos. | pmid:12642464 |
Ozalp C et al. | Bimolecular fluorescence complementation analysis of cytochrome p450 2c2, 2e1, and NADPH-cytochrome p450 reductase molecular interactions in living cells. | 2005 | Drug Metab. Dispos. | pmid:15980100 |
Graham RA et al. | In vivo and in vitro induction of cytochrome P450 enzymes in beagle dogs. | 2002 | Drug Metab. Dispos. | pmid:12386126 |
Castle PJ et al. | Human liver lauric acid hydroxylase activities. | 1995 | Drug Metab. Dispos. | pmid:8654190 |
Yang YH et al. | Heterologous expression of CYP2K1 and identification of the expressed protein (BV-CYP2K1) as lauric acid (omega-1)-hydroxylase and aflatoxin B1 exo-epoxidase. | 2000 | Drug Metab. Dispos. | pmid:11038153 |
Poloyac SM et al. | The effect of isoniazid on CYP2E1- and CYP4A-mediated hydroxylation of arachidonic acid in the rat liver and kidney. | 2004 | Drug Metab. Dispos. | pmid:15205388 |
Buhler DR et al. | The regiospecific hydroxylation of lauric acid by rainbow trout (Oncorhynchus mykiss) cytochrome P450s. | 1997 | Drug Metab. Dispos. | pmid:9321521 |
Grillo MP and Lohr MT | Covalent binding of phenylacetic acid to protein in incubations with freshly isolated rat hepatocytes. | 2009 | Drug Metab. Dispos. | pmid:19196839 |
Grillo MP et al. | Stereoselective flunoxaprofen-S-acyl-glutathione thioester formation mediated by acyl-CoA formation in rat hepatocytes. | 2010 | Drug Metab. Dispos. | pmid:19786506 |
Li C et al. | Covalent binding of 2-phenylpropionyl-S-acyl-CoA thioester to tissue proteins in vitro. | 2003 | Drug Metab. Dispos. | pmid:12756204 |
Albro PW et al. | In vitro metabolism of mono-2-ethylhexyl phthalate by microsomal enzymes. Similarity to omega- and (omega-1) oxidation of fatty acids. | 1984 Nov-Dec | Drug Metab. Dispos. | pmid:6150824 |
Okita RT and Masters BS | Effect of phenobarbital treatment and cytochrome P-450 inhibitors on the laurate omega- and (omega - 1)-hydroxylase activities of rat liver microsomes. | 1980 May-Jun | Drug Metab. Dispos. | pmid:6104577 |
Dell HD et al. | Etofenamate fatty acid asters. An example of a new route of drug metabolism. | 1982 Jan-Feb | Drug Metab. Dispos. | pmid:6124384 |
Orton TC and Parker GL | The effect of hypolipidemic agents on the hepatic microsomal drug-metabolizing enzyme system of the rat. Induction of cytochrome(s) P-450 with specificity toward terminal hydroxylation of lauric acid. | 1982 Mar-Apr | Drug Metab. Dispos. | pmid:6124394 |
Raza H and Levine WG | Azoreduction of N,N-dimethyl-4-aminoazobenzene (DAB) by rat hepatic microsomes. Selective induction by clofibrate. | 1986 Jan-Feb | Drug Metab. Dispos. | pmid:2868860 |
Levine WG and Raza H | Mechanism of azoreduction of dimethylaminoazobenzene by rat liver NADPH-cytochrome P-450 reductase and partially purified cytochrome P-450. Oxygen and carbon monoxide sensitivity and stimulation by FAD and FMN. | 1988 May-Jun | Drug Metab. Dispos. | pmid:2900738 |
Yamaura Y et al. | Predicting oxidation sites with order of occurrence among multiple sites for CYP4A-mediated reactions. | 2011 | Drug Metab. Pharmacokinet. | pmid:21422671 |
Hayashi S et al. | Essential role of singlet oxygen species in cytochrome P450-dependent substrate oxygenation by rat liver microsomes. | 2005 | Drug Metab. Pharmacokinet. | pmid:15770071 |
Yasui H et al. | Evidence for singlet oxygen involvement in rat and human cytochrome P450-dependent substrate oxidations. | 2002 | Drug Metab. Pharmacokinet. | pmid:15618693 |
Yamazaki H et al. | Activities of cytochrome p450 enzymes in liver and kidney microsomes from systemic carnitine deficiency mice with a gene mutation of carnitine/organic cation transporter. | 2002 | Drug Metab. Pharmacokinet. | pmid:15618652 |
Parkinson A et al. | On the mechanism of hepatocarcinogenesis of benzodiazepines: evidence that diazepam and oxazepam are CYP2B inducers in rats, and both CYP2B and CYP4A inducers in mice. | 2006 | Drug Metab. Rev. | pmid:16684660 |
Imai Y et al. | Structure-function relationships of cytochrome P-450 laurate (omega-1)-hydroxylase. | 1989 | Drug Metab. Rev. | pmid:2680391 |
Noble MA et al. | Analysis of the interactions of cytochrome b5 with flavocytochrome P450 BM3 and its domains. | 2007 | Drug Metab. Rev. | pmid:17786641 |
Miko M and DevÃnsky F | Biochemical basis of cytotoxic activity of some new N'-oxides of N',N'-dimethylaminoalkylamides of dodecanoic acid. | 1992 | Drug Metabol Drug Interact | pmid:1424644 |
Otomo S et al. | Prostaglandin E1 incorporated in lipid microspheres (lipo PGE1). | 1985 | Drugs Exp Clin Res | pmid:3880049 |
Goto J et al. | A comparison of the effect of Lipo PGE1 and other related compounds on experimental peripheral arterial occlusive disease in rats. | 1986 | Drugs Exp Clin Res | pmid:3816509 |
Wikström M | [Nobel prize laureate in chemistry]. | 1978 | Duodecim | pmid:729494 |
Cao J et al. | Evaluation of the addition of various surfactant-suspended carbon nanotubes in MEEKC with an in situ-synthesized surfactant system. | 2011 | Electrophoresis | pmid:21254135 |
Petersson P et al. | Direct coupling of micellar electrokinetic chromatography to mass spectrometry using a volatile buffer system based on perfluorooctanoic acid and ammonia. | 2003 | Electrophoresis | pmid:12658688 |
The Endocrine Society 2009 Laureate Awards. | 2009 | Endocr. Rev. | pmid:19663077 | |
The Endocrine Society Laureate Awards. | 2009 | Endocr. Rev. | pmid:19663075 | |
The Endocrine Society 2012 Laureate Awards. | 2012 | Endocr. Rev. | pmid:23038815 | |
The Endocrine Society Laureate Awards. | 2012 | Endocr. Rev. | pmid:23038814 | |
The Endocrine Society 2007 Laureate Awards. | 2007 | Endocr. Rev. | pmid:17722366 | |
The Endocrine Society Laureate Awards. | 2007 | Endocr. Rev. | pmid:17722365 | |
The Endocrine Society 2011 Laureate Awards. | 2011 | Endocr. Rev. | pmid:21932463 | |
The Endocrine Society Laureate Awards. | 2011 | Endocr. Rev. | pmid:21932462 | |
Nishi Y et al. | Ingested medium-chain fatty acids are directly utilized for the acyl modification of ghrelin. | 2005 | Endocrinology | pmid:15677766 |